MASH Diagnostics: Advances, Limitations, and the Path Ahead (Session 1)
Nov
10
2025
Convention Center: Ballroom A, Level 3
8:00 AM
- 9:30 AM
World Class Speakers
Description
Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.
Journey Maps
Presentations
8:00 AM
- 8:15 AM
Oct
09
2026
Convention Center - Ballroom A, Level 3
Large-Scale Multi-trait GWAS Links OPA1 Gene to Liver Fibrosis and MASLD
Mazen Noureddin
, Abstract Presenter
MASLD
8:15 AM
- 8:30 AM
Oct
09
2026
Convention Center - Ballroom A, Level 3
Diagnostic and clinical implications of high spleen-to-liver stiffness ratio in MASLD – a prospective, comparative study
Naim Alkhouri, MD, FAASLD
, Abstract Presenter
MASLD
8:30 AM
- 8:45 AM
Oct
09
2026
Convention Center - Ballroom A, Level 3
Distinguishing MASLD and MetALD/ALD Using Phosphatidylethanol and Non-Invasive Tests: A Multicenter Cohort Analysis
Mazen Noureddin
, Abstract Presenter
MASLD
8:45 AM
- 9:00 AM
Oct
09
2026
Convention Center - Ballroom A, Level 3
Screening pathways using non-invasive tests of liver fibrosis in steatotic liver diseases: is it time to update the guidelines?
Mark Muthiah, MBBS, FRCP (Edin.), FAMS, MMed, PhD
, Abstract Presenter
MASLD
9:00 AM
- 9:15 AM
Oct
09
2026
Convention Center - Ballroom A, Level 3
Utility of FIB-4, Agile 4, and Platelet Count to Rule Out Cirrhosis on Biopsy in Patients with LSM Between 15-25 kPa: A Multi-Center Cohort Study
Naim Alkhouri, MD, FAASLD
, Abstract Presenter
MASLD
Objectives
- Review recent advancements in noninvasive diagnostic tools and biomarkers for MASH, including their clinical utility and validation status.
- Discuss limitations, uncertainties, and practical challenges in implementing MASH diagnostics in clinical and research settings.